Biosimilar market will exhibit a CAGR of around 32.00 % for the forecast period 2029
Biosimilar Market – Industry Trends and Forecast to 2029
Global Biosimilar Market, By Product Type (Magnetic Resonance Imaging Scanners, Computed Tomography Scanners, Position Emission Tomography Scanners, Biosimilar (EEG), Electromyography Devices (EMG), Magnetoencphalography Devices, Transcranial Doppler Devices, Intracranial Pressure Monitors (ICP), Electrodes, Sensors, Gels and Cables), Drug Class (Insulin, Recombinant Human Growth Hormone (RHGH), Granulocyte Colony-Stimulating Factor, Interferon, Erythropoietin, Etanercept, Monoclonal Antibodies, Follitropin, Glucagon, Calcitonin, Teriparatide, Enoxaparin Sodium), Type of Manufacturing (In-House Manufacturing and Contract Manufacturing), Procedure (Invasive and Non-Invasive), Disease (Stroke, Dementia and Epilepsy), Indication (Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Patent Foramen Ovale (PFO), Aortic Valve Stenosis and Others), Therapy Type (Oncology, Immunology, Haematology, Hormone Therapy, Metabolic Disorders, and Others), End Users (Hospitals, Clinics, Diagnostic Centres and Others)– Industry Trends and Forecast to 2029
Market Analysis and Size
· Biosimilar market is expected to undergo a CAGR of 32.00% during the forecast period of 2022-2029. This indicates that the market value, which was USD 37,270.20 million in 2021, would rocket up to USD 343,520.90 million by 2029. “Oncology” dominates the therapy type segment of the Biosimilar market owing to the increase in number of research studies, increasing research and development activities by key players focused on oncology and advancements in healthcare technologies. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Global Biosimilar Market Scope
The Biosimilar market is segmented on the basis of product type, drug class, type of manufacturing, procedure, disease, indication, therapy type and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product type
· Magnetic Resonance Imaging Scanners
· Computed Tomography Scanners
· Position Emission Tomography Scanners
· Biosimilar (EEG)
· Electromyography Devices (EMG)
· Magnetoencphalography Devices
· Transcranial Doppler Devices
· Intracranial Pressure Monitors (ICP)
· Electrodes
· Sensors
· Gels
· Cables
Based on product type, Biosimilar market is segmented into MRI scanners, CT scanners, PET scanners, Biosimilar (EEG), electromyography devices (EMG), MEG devices, TCD devices, intracranial pressure monitors (ICP), electrodes, sensors, gels and cables.
Drug class
· Insulin
· Recombinant Human Growth Hormone (RHGH)
· Granulocyte Colony-Stimulating Factor
· Interferon
· Erythropoietin
· Etanercept
· Monoclonal Antibodies
· Follitropin
· Glucagon
· Calcitonin
· Teriparatide
· Enoxaparin Sodium
On the basis of drug class, the Biosimilar market is segmented into insulin, recombinant human growth hormone (RHGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, monoclonal antibodies, follitropin, glucagon, calcitonin, teriparatide and enoxaparin sodium. Monoclonal antibodies segment is sub-segmented into rituximab, infliximab, adalimumab, trastuzumab and other monoclonal antibodies.
Type of manufacturing
· In-House Manufacturing
· Contract Manufacturing
On the basis of type of manufacturing, the Biosimilar market is segmented into in-house manufacturing and contract manufacturing.
Procedure
· Invasive
· Non-Invasive
Based on procedure, Biosimilar market is segmented into Invasive and non-invasive.
Disease
· Stroke
· Dementia
· Epilepsy
On the basis of disease, the Biosimilar market is segmented into stroke, dementia and epilepsy.
Indication
· Atrial Septal Defect (ASD)
· Ventricular Septal Defect (VSD)
· Patent Foramen Ovale (PFO)
· Aortic Valve Stenosis
· Others
On the basis of indication, the Biosimilar market is segmented into atrial septal defect (ASD), ventricular septal defect (VSD), patent foramen ovale (PFO), aortic valve stenosis and others.
Therapy type
· Oncology
· Immunology
· Haematology
· Hormone Therapy
· Metabolic Disorders
· Others
On the basis of therapy type, the Biosimilar market is segmented into oncology, immunology, haematology, hormone therapy, metabolic disorders, and others.
End users
· Hospitals
· Clinics
· Diagnostic Centres
· Others
On the basis of end users, the Biosimilar market is segmented into hospitals, clinics, diagnostic centres and others.
Get the sample copy of Report here: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-biosimilar-market
Biosimilar Market Regional Analysis/Insights
The countries covered in the Biosimilar market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Competitive Landscape and Biosimilar Market Share Analysis
The Biosimilar market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Biosimilar market.
Some of the major players operating in the Biosimilar market are
· Novartis AG (Switzerland),
· Orion Pharma AB (Sweden),
· Pfizer Inc. (US),
· Samsung Bioepis. (South Korea),
· Coherus BioSciences, Inc. (US),
· Amgen Inc. (US),
· Eli Lilly and Company. (US),
· Takeda Pharmaceutical Company Limited. (Japan),
· Bristol-Myers Squibb Company (US)
Full Access of Report @ https://www.databridgemarketresearch.com/reports/global-biosimilar-market
MAJOR TOC OF THE REPORT
· INTRODUCTION
· MARKET SEGMENTATION
· EXECUTIVE SUMMARY
· PREMIUM INSIGHTS
· MARKET OVERVIEW
· QUESTIONNAIRE
Get TOC Details
https://www.databridgemarketresearch.com/toc/?dbmr=global-biosimilar-market
BROWSE RELATED REPORTS
· The IoT sensor market is expected to witness market growth at a rate of 30.05% in the forecast period of 2021 to 2028. Data Bridge Market Research report on IoT sensor market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The rise in the demand for connected and wearables devices is escalating the growth of IoT sensor market.
https://www.databridgemarketresearch.com/reports/asia-pacific-iot-sensor-market
· The IoT sensor market is expected to witness market growth at a rate of 37.6% in the forecast period of 2021 to 2028. Data Bridge Market Research report on IoT sensor market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth.
https://www.databridgemarketresearch.com/reports/north-america-iot-sensor-market
· Data Bridge Market Research analyses the Middle East and Africa IoT Sensor Market will exhibit a CAGR of 34.8% for the forecast period of 2021-2028.
https://www.databridgemarketresearch.com/reports/middle-east-and-africa-iot-sensor-market
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Sopan.gedam@databridgemarketresearch.com
